Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Real-world experience of sequential therapies including cytokine/immunotherapy of metastatic renal cell carcinoma in Taiwan

Date

19 Dec 2015

Session

Poster presentation 1

Presenters

Jason Chia-Hsun Hsieh

Citation

Annals of Oncology (2015) 26 (suppl_9): 71-79. 10.1093/annonc/mdv524

Authors

J.C. Hsieh1, W.J. Chang2

Author affiliations

  • 1 Internal Medicine, Chang Gung Memorial Hospital-Linkou, 333 - Taoyuan/TW
  • 2 Internal Medicine, Division Of Oncology, Chang Gung Memorial Hospital-Linkou, 333 - Taoyuan/TW
More

Resources

Abstract 1369

Aim/Background

The rapid development of new drugs, the overall survival of patients with metastatic renal cell carcinoma (mRCC) has increased over the last decade. However, resistance to these agents would acquire inevitably. Two of the important strategies to overcome the drug resistance is the optimization of the drug sequence and combination therapy with a variety of novel drugs. In this study, we aimed to describe and analyze the drug sequence and the survivals on a real-world basis.

Methods

Since 2005 to 2015, we retrospectively analyzed patients with mRCC who received at least 2 lines of anticancer therapies in Chang Gung Memorial hospital at Linkou in Taiwan. Basic characteristics were collected from medical records. Student t test, Kaplan-Meier survival analysis with log-rank test and Cox-regression model analysis were used.

Results

A total of 74 patients were retrieved for analysis from the databank. The most common first-line treatment was sunitinib (n = 44, 59.5%) and median progression-free survival 1(PFS1) of sunitinib was 7.9 (95% confidence interval [CI]: 5.8-10.8) months. The most common second-line treatment was everolimus, and its median PFS2 was 6.4 (95% CI: 1.2-11.6) months. Most intriguingly, no matter which line of immunotherapy (interleukin-2) or cytokine therapy (interferon) was used; patients exposed to one line of cytokine/immunotherapy would have significant better survivals than those who never exposed to it. (Log rank test, P = 0.003) In addition, patients having a PFS1 less than 6.7 months would have worse overall survivals (OS). (Log rank test, P = 0.0028) Patients who fit the sequence of sunitinib followed by everolimus have a PFS1 + PFS2 of 16.9 and a OS of 30.4 months, respectively.

Conclusions

Our data suggested adding cytokine/immunotherapy into current sequential targeted therapies as any line of treatment might improve overall survivals.

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings